Published in Hepatology on August 01, 2001
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Int (2007) 1.10
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS (2009) 1.01
Future prospectives for the management of chronic hepatitis B. World J Gastroenterol (2007) 0.91
New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg (2002) 0.91
Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol (2007) 0.87
Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol (2016) 0.85
A meta-analysis of nucleos(t)ide analogues in patients with decompensated cirrhosis due to hepatitis B. Dig Dis Sci (2012) 0.82
Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci (2005) 0.81
Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob (2006) 0.81
Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol (2011) 0.81
The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosis. PLoS One (2012) 0.80
Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus: a case report. World J Gastroenterol (2007) 0.79
Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis. Clin Exp Med (2016) 0.78
Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol (2009) 0.78
Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients. Comp Hepatol (2007) 0.78
Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis. World J Hepatol (2015) 0.78
Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol (2013) 0.77
The effectiveness of lamivudine treatment in cirrhotic patients with HBV precore mutations: a prospective, open-label study. Dig Dis Sci (2006) 0.77
Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. Transplantation (2015) 0.75
Emerging drugs for hepatitis B. Expert Opin Emerg Drugs (2007) 0.75
The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy. Clin Cancer Drugs (2015) 0.75
What is the optimal regimen for preventing hepatitis B recurrence after liver transplantation? Nat Clin Pract Gastroenterol Hepatol (2008) 0.75
Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. J Korean Med Sci (2005) 0.75
Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. J Clin Transl Hepatol (2017) 0.75
Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV. Dig Dis Sci (2008) 0.75
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology (2001) 6.19
An urgent remedy needed. Br Dent J (1991) 5.42
Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med (1987) 4.08
Patient, center and geographic characteristics of nationally placed livers. Am J Transplant (2012) 3.16
Patent foramen ovale in young stroke patients. Lancet (1988) 2.68
HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant (2007) 2.50
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther (2014) 2.18
Ligandin heterogeneity : evidence that the two non-identical subunits are the monomers of two distinct proteins. Biochim Biophys Acta (1977) 2.03
Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant (2007) 2.00
Dental notations. Br Dent J (2000) 1.91
Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant (2014) 1.62
A randomized trial of exercise and dietary counseling after liver transplantation. Am J Transplant (2006) 1.61
Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Ann Intern Med (2000) 1.43
Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology (1992) 1.41
Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol (2000) 1.38
Function and regulation of hepatic and intestinal fatty acid binding proteins. Chem Phys Lipids (1985) 1.36
A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations. J Clin Endocrinol Metab (2014) 1.34
Left atrial myxoma diagnosed by echocardiography, with observations on tumour movement. Br Heart J (1973) 1.28
Cloning of a cDNA encoding rat intestinal fatty acid binding protein. Proc Natl Acad Sci U S A (1984) 1.28
Mutation of human keratin 18 in association with cryptogenic cirrhosis. J Clin Invest (1997) 1.24
Functions of fatty acid binding proteins. Experientia (1990) 1.21
Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology (1996) 1.19
Nuclear magnetic resonance imaging of experimentally induced liver disease. Radiology (1983) 1.16
Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. Am J Transplant (2008) 1.13
Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther (2011) 1.12
Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology (1998) 1.11
Long-standing asymptomatic primary sclerosing cholangitis: report of three cases. Dig Dis Sci (1981) 1.08
Mechanisms of regulation of liver fatty acid-binding protein. Mol Cell Biochem (1993) 1.07
Induction of peroxisomal fatty acid beta-oxidation and liver fatty acid-binding protein by peroxisome proliferators. Mediation via the cytochrome P-450IVA1 omega-hydroxylase pathway. J Biol Chem (1993) 1.07
Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant (2010) 1.05
Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J Viral Hepat (2011) 1.04
Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology (1985) 1.04
The immunobiology of bile and biliary epithelium. Hepatology (1999) 1.04
Light microscopic immunocytochemical localization of hepatic and intestinal types of fatty acid-binding proteins in rat small intestine. J Lipid Res (1986) 1.01
Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier. J Clin Invest (1997) 1.00
Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system. Am J Transplant (2010) 0.99
Regulation of the biosynthesis of two distinct fatty acid-binding proteins in rat liver and intestine. Influences of sex difference and of clofibrate. J Biol Chem (1985) 0.98
Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology (1995) 0.97
Streptokinase in acute myocardial infarction: a controlled multicentre study in the United Kingdom. Br Med J (1976) 0.96
Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation. Gastroenterology (1996) 0.96
Gender differences in liver donor quality are predictive of graft loss. Am J Transplant (2011) 0.96
Transfer of fluorescent fatty acids from liver and heart fatty acid-binding proteins to model membranes. J Biol Chem (1990) 0.95
Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol (2000) 0.95
Tissue expression of three structurally different fatty acid binding proteins from rat heart muscle, liver, and intestine. Biochem Biophys Res Commun (1986) 0.95
Advanced gastroduodenal polyposis with ras mutations in a patient with familial adenomatous polyposis. Hum Pathol (1993) 0.94
Immunohistological localization of ligandin in human tissues. Cancer (1980) 0.93
Intestinal fatty acid binding protein may favor differential apical fatty acid binding in the intestine. Biochim Biophys Acta (2000) 0.93
Fatty-acid metabolism and the pathogenesis of hepatocellular carcinoma: review and hypothesis. Hepatology (1993) 0.93
Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther (2013) 0.92
Induction of fatty acid binding protein by peroxisome proliferators in primary hepatocyte cultures and its relationship to the induction of peroxisomal beta-oxidation. Biochim Biophys Acta (1990) 0.92
Radioimmunoassay of human ligandin. Hepatology (1983) 0.91
Results of early mobilization and discharge after myocardial infarction. Br Med J (1973) 0.91
'Treatment of Class II malocclusions with removable appliances. Part 3. Functional appliance therapy'. Br Dent J (1990) 0.90
Radioimmunoassay of plasma ligandin: a sensitive index of experimental hepatocellular necrosis. Gastroenterology (1978) 0.90
Fetal epidermal differentiation and barrier development In vivo is accelerated by nuclear hormone receptor activators. J Invest Dermatol (1999) 0.89
Down-regulation of liver and heart specific fatty acid binding proteins by endotoxin and cytokines in vivo. Biochim Biophys Acta (1999) 0.89
Turnover and short-term regulation of fatty acid binding protein in liver. J Biol Chem (1985) 0.88
Echocardiography in assessment of infants with complete d-transposition of great arteries. Br Heart J (1978) 0.88
Radioimmunoassay of ligandin. Biochim Biophys Acta (1977) 0.87
Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol (1996) 0.87
The primary structure of fatty-acid-binding protein from nurse shark liver. Structural and evolutionary relationship to the mammalian fatty-acid-binding protein family. Eur J Biochem (1992) 0.86
Artificial liver support devices for fulminant liver failure. Clin Liver Dis (2001) 0.85
A methylsulfonyl metabolite of a polychlorinated biphenyl can serve as a ligand for liver fatty acid binding protein in rat intestinal mucosa. Chem Biol Interact (1991) 0.84
The synthetic hydroxyproline-containing collagen analogue (Gly-Pro-Hyp)10 promotes enzymatic activity of matrixmetalloproteinase-2 in vitro. Eur J Microbiol Immunol (Bp) (2012) 0.84
Fine-resolution mapping by haplotype evaluation: the examples of PFIC1 and BRIC. Hum Genet (1999) 0.84
Sterol carrier protein 2 and fatty acid-binding protein. Separate and distinct physiological functions. J Biol Chem (1985) 0.84
Chronic intrahepatic cholestasis due to sarcoidosis. Gut (1982) 0.84
Management of hepatitis C in liver transplant recipients. Am J Transplant (2006) 0.83
Chronic liver disease: evaluation by magnetic resonance. Radiology (1984) 0.83
Revision of the blocked N terminus of rat heart fatty acid-binding protein by liquid secondary ion mass spectrometry. J Biol Chem (1988) 0.83
Diffuse intrahepatic biliary strictures in sarcoidosis resembling sclerosing cholangitis. Case report and review of the literature. Dig Dis Sci (1997) 0.83
Studies of the fatty acid-binding site of rat liver fatty acid-binding protein using fluorescent fatty acids. J Biol Chem (1989) 0.82
Solid organ transplantation in HIV-positive patients. Transplant Proc (2001) 0.81
Mechanism-based probes of the topology and function of fatty acid hydroxylases. FASEB J (1992) 0.81
Antienvelope antibodies are protective against GBV-C reinfection: evidence from the liver transplant model. J Med Virol (1998) 0.81
Wilson's disease. Clinical correction with cranial computed tomography. Neuroradiology (1981) 0.81
Partial purification of molecular weight 12 000 fatty acid binding proteins from rat brain and their effect on synaptosomal Na+-dependent amino acid uptake. Biochemistry (1984) 0.80
Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation (2000) 0.80
Metabolism of 15-hydroxyeicosatetraenoic acid by Caco-2 cells. J Lipid Res (1990) 0.79
Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig Dis Sci (2000) 0.79
Evidence for a novel keratinocyte fatty acid uptake mechanism with preference for linoleic acid: comparison of oleic and linoleic acid uptake by cultured human keratinocytes, fibroblasts and a human hepatoma cell line. Biochim Biophys Acta (1994) 0.78
Ligandin concentrations in the steroidogenic tissues of the rat during development. Biochim Biophys Acta (1984) 0.78
Autonomic nervous system tone measured by baroreflex sensitivity is depressed in patients with end-stage liver disease. Am J Gastroenterol (1999) 0.78
Fatty acid binding sites of rodent adipocyte and heart fatty acid binding proteins: characterization using fluorescent fatty acids. Biochemistry (1990) 0.78
Dento-facial orthopaedics in the correction of class II malocclusion. Br J Orthod (1982) 0.78
Structural characterization and functional effects of a circulating heparan sulfate in a patient with hepatocellular carcinoma. Am J Hematol (1998) 0.77
Immunological identity of rat liver cytosolic heme-binding protein with purified and recombinant liver fatty acid binding protein by western blots of two-dimensional gels. Biochem Biophys Res Commun (1994) 0.77
Fatty acid binding proteins in the three types of rat skeletal muscle. Proc Soc Exp Biol Med (1988) 0.77
Subdural empyema after endoscopic sclerotherapy. Am J Med (1989) 0.77
Hepatitis after liver transplantation: the role of the known and unknown viruses. Liver Transpl Surg (1998) 0.77
Standard sequential immunosuppression with Minnesota antilymphoblast globulin and cyclosporine vs FK 506: a comparison of early nephrotoxicity. Transplant Proc (1993) 0.77
Fatty acid binding proteins: recent concepts of regulation and function. Prog Clin Biol Res (1992) 0.77
Hepatitis G virus in patients with cryptogenic liver disease undergoing liver transplantation. Hepatology (1997) 0.77
Expression of fatty acid binding protein in the liver during pregnancy and lactation in the rat. Biochim Biophys Acta (1995) 0.76
Severe hyperbilirubinemia after creation of transjugular intrahepatic portosystemic shunts: natural history and predictors of outcome. Ann Intern Med (1998) 0.76
Orthopedic coordination of dentofacial development in skeletal Class II malocclusion in conjunction with edgewise therapy. Part I. Am J Orthod (1983) 0.76
Intravenous albumin for spontaneous bacterial peritonitis in patients with cirrhosis. N Engl J Med (1999) 0.76
Isolation and characterization of fatty acid binding proteins from mammary tissue of lactating rats. Biochem J (1988) 0.76